Research Progress of Multi-target CAR-T Cell Therapy for Cancer

JIANG Yao; WEN Weihong; YANG Fa; NIE Disen; ZHANG Wuhe; QIN Weijun

doi:10.3971/j.issn.1000-8578.2022.21.1224

Cancer Research on Prevention and Treatment > 2022 > 49(7): 709-714. > DOI: 10.3971/j.issn.1000-8578.2022.21.1224

JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun. Research Progress of Multi-target CAR-T Cell Therapy for Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 709-714. DOI: 10.3971/j.issn.1000-8578.2022.21.1224

Citation:

PDF (2948 KB)

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

1.
Department of Urology, Xijing Hospital of Air Force Military Medical University, Xi'an 710054, China
2.
Medical Research Institute of Northwestern Polytechnical University, Xi'an 710000, China
3.
Department of Urology, Air Force 986 Hospital, Xi'an 710054, China

Funding:

National Natural Science Foundation of China 82173204

Innovation Capability Support Program of Shaanxi 2020PT-021

Special Funds of Fundamental Research for The Central Universities G2021KY05102

More Information

Corresponding author:
QIN Weijun, E-mail: qinwj@fmmu.edu.cn
Received Date: October 31, 2021
Revised Date: February 07, 2022
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors. CAR-T cell therapy has shown remarkable antitumor efficacy for the treatment of tumors, especially for hematological malignancies, but is less effective in solid tumors. Single-target CAR-T is prone to off-target effect during application, and there is a risk of relapse or more refractory treatment. The development of double-target or multi-target CAR-T is expected to extend the antigen coverage of target cells, effectively avoids antigen escape and prevents tumor recurrence, and prolongs the survival time of patients. This article reviews the advances of multi-target chimeric antigen receptor T cell, and discusses the prospect of its development.
- Malignant tumor,
- CAR-T cell,
- Off-target effects

FullText(HTML)

Competing interests: The authors declared that they have no competing interests.

References (43)

References

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	Kiani J, Naderi M, Torabi-Rahvar M, et al. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells[J]. Arch Iran Med, 2019, 22(1): 7-10.
[3]	Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16): 1509-1518. doi: 10.1056/NEJMoa1215134
[4]	黄河, 黄玥, 胡永仙, 等. 嵌合抗原受体T细胞治疗后急性淋巴细胞白血病复发的研究进展[J]. 浙江医学, 2020, 42(23): 2487-2494. doi: 10.12056/j.issn.1006-2785.2020.42.23.2020-3420 Huang H, Huang Y, Hu YX, et al. Advances in the study of acute lymphoblastic leukemia recurrence after chimeric antigen receptor T cell therapy[J]. Zhejiang Yi Xue, 2020, 42(23): 2487-2494. doi: 10.12056/j.issn.1006-2785.2020.42.23.2020-3420
[5]	Hou B, Tang Y, Li W, et al. Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis[J]. Dis Markers, 2019, 2019: 3425291.
[6]	Junghans RP, Ma Q, Rathore R, et al. PhaseⅠTrial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response[J]. Prostate, 2016, 76(14): 1257-1270. doi: 10.1002/pros.23214
[7]	Feng K, Guo Y, Dai H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer[J]. Sci China Life Sci, 2016, 59(5): 468-479. doi: 10.1007/s11427-016-5023-8
[8]	Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma[J]. N Engl J Med, 2017, 377(26): 2531-2544. doi: 10.1056/NEJMoa1707447
[9]	O'Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvⅢ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J]. Sci Transl Med, 2017, 9(399): eaaa0984. doi: 10.1126/scitranslmed.aaa0984
[10]	Ahmed N, Brawley V, Hegde M, et al. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial[J]. JAMA Oncol, 2017, 3(8): 1094-1101. doi: 10.1001/jamaoncol.2017.0184
[11]	Zhang C, Wang Z, Yang Z, et al. PhaseⅠ Escalating-Dose Trial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers[J]. Mol Ther, 2017, 25(5): 1248-1258. doi: 10.1016/j.ymthe.2017.03.010
[12]	Park JH, Rivière I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2018, 378(5): 449-459. doi: 10.1056/NEJMoa1709919
[13]	Beatty GL, O'Hara MH, Lacey SF, et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a PhaseⅠTrial[J]. Gastroenterology, 2018, 155(1): 29-32. doi: 10.1053/j.gastro.2018.03.029
[14]	Guo Y, Feng K, Liu Y, et al. PhaseⅠStudy of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers[J]. Clin Cancer Res, 2018, 24(6): 1277-1286. doi: 10.1158/1078-0432.CCR-17-0432
[15]	Wang Y, Chen M, Wu Z, et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial[J]. Oncoimmunology, 2018, 7(7): e1440169. doi: 10.1080/2162402X.2018.1440169
[16]	Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma[J]. Proc Natl Acad Sci U S A, 2019, 116(19): 9543-9551. doi: 10.1073/pnas.1819745116
[17]	Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma[J]. N Engl J Med, 2020, 382(14): 1331-1342. doi: 10.1056/NEJMoa1914347
[18]	Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial[J]. Cytotherapy, 2020, 22(10): 573-580. doi: 10.1016/j.jcyt.2020.04.088
[19]	Ruella M, Barrett DM, Kenderian SS, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies[J]. J Clin Invest, 2016, 126(10): 3814-3826. doi: 10.1172/JCI87366
[20]	Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies[J]. Blood, 2020, 135(1): 17-27. doi: 10.1182/blood.2019000017
[21]	Han X, Wang Y, Wei J, et al. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 128. doi: 10.1186/s13045-019-0813-7
[22]	Ko AH, Jordan AC, Tooker E, et al. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer[J]. Mol Ther, 2020, 28(11): 2367-2378. doi: 10.1016/j.ymthe.2020.07.017
[23]	Feng KC, Guo YL, Liu Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma[J]. J Hematol Oncol, 2017, 10(1): 4. doi: 10.1186/s13045-016-0378-7
[24]	Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells[J]. Nat Biotechnol, 2013, 31(1): 71-75. doi: 10.1038/nbt.2459
[25]	Golubovskaya V, Zhou H, Li F, et al. Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma[J]. Cancers (Basel), 2021, 13(5): 981. doi: 10.3390/cancers13050981
[26]	Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial[J]. Nat Med, 2020, 26(10): 1569-1575. doi: 10.1038/s41591-020-1081-3
[27]	Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma[J]. Nat Commun, 2020, 11(1): 2283. doi: 10.1038/s41467-020-16160-5
[28]	Li T, Wang J. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice[J]. BMC Cancer, 2020, 20(1): 678. doi: 10.1186/s12885-020-07180-x
[29]	Yuan X, Sun Z, Yuan Q, et al. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors[J]. Invest New Drugs, 2021, 39(1): 34-51. doi: 10.1007/s10637-020-00978-3
[30]	Zhao W, Jia L, Zhang M, et al. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer[J]. Am J Cancer Res, 2019, 9(8): 1846-1856.
[31]	Jiang W, Li T, Guo J, et al. Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma[J]. Front Oncol, 2021, 11: 546586. doi: 10.3389/fonc.2021.546586
[32]	Fousek K, Watanabe J, Joseph SK, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression[J]. Leukemia, 2021, 35(1): 75-89. doi: 10.1038/s41375-020-0792-2
[33]	Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma[J]. Neuro Oncol, 2018, 20(4): 506-518. doi: 10.1093/neuonc/nox182
[34]	Sukumaran S, Watanabe N, Bajgain P, et al. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment[J]. Cancer Discov, 2018, 8(8): 972-987. doi: 10.1158/2159-8290.CD-17-1298
[35]	Greco R, Oliveira G, Stanghellini MT, et al. Improving the safety of cell therapy with the TK-suicide gene[J]. Front Pharmacol, 2015, 6: 95.
[36]	Klopp A, Schreiber S, Kosinska AD, et al. Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B[J]. Front Immunol, 2021, 12: 734246. doi: 10.3389/fimmu.2021.734246
[37]	Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity[J]. Sci Transl Med, 2014, 6(261): 261ra151.
[38]	Brown CE, Alizadeh D, Starr R, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy[J]. N Engl J Med, 2016, 375(26): 2561-2569. doi: 10.1056/NEJMoa1610497
[39]	Wang Y, Wang J, Yang X, et al. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model[J]. Front Immunol, 2021, 12: 628906. doi: 10.3389/fimmu.2021.628906
[40]	Cao Y, Xiao Y, Wang N, et al. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas[J]. Transplantat Cell Ther, 2021, 27(11): 910. e1-910. e11. doi: 10.1016/j.jtct.2021.08.012
[41]	韩佳轩, 赵云. 声动力联合热疗抗肿瘤机制及其在肿瘤中的应用[J]. 肿瘤防治研究, 2022, 49(1): 78-82. doi: 10.3971/j.issn.1000-8578.2022.21.1013 Han JX, Zhao Y. Anti-tumor Mechanism of Sonodynamic Combined with Hyperthermia and Its Application in Tumor[J]. Zhong Liu Fang Zhi Yan Jiu, 2022, 49(1): 78-82. doi: 10.3971/j.issn.1000-8578.2022.21.1013
[42]	Chen Q, Hu Q, Dukhovlinova E, et al. Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells[J]. Adv Mater, 2019, 31(23): e1900192.
[43]	Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma[J]. Nat Commun, 2020, 11(1): 2283.

Cited By

Tables(1)

Get Citation

PDF

XML

Article views (3378) PDF downloads (1514)

Turn off MathJax

Article Contents

Abstract

References

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Abstract

References

Catalog

Download Center

Links

Contact Us

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Abstract

References

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content